Aptevo Therapeutics Inc (NASDAQ:APVO) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokers have set a one year consensus price target of $6.00 for the company and are predicting that the company will post ($0.32) earnings per share for the current quarter, according to Zacks. Zacks has also given Aptevo Therapeutics an industry rank of 194 out of 265 based on the ratings given to its competitors.
A number of research firms have recently commented on APVO. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, October 12th. Piper Jaffray Companies reissued an “overweight” rating and issued a $6.00 price objective on shares of Aptevo Therapeutics in a research note on Thursday, October 5th.
Several institutional investors and hedge funds have recently bought and sold shares of APVO. Precept Management LLC bought a new stake in shares of Aptevo Therapeutics in the 2nd quarter worth $1,210,000. Legal & General Group Plc raised its stake in shares of Aptevo Therapeutics by 11,751.3% in the 2nd quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock worth $815,000 after buying an additional 390,379 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Aptevo Therapeutics by 8.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock worth $2,187,000 after buying an additional 78,109 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Aptevo Therapeutics by 87.2% in the 4th quarter. Acadian Asset Management LLC now owns 67,799 shares of the biotechnology company’s stock worth $287,000 after buying an additional 31,578 shares in the last quarter. 32.28% of the stock is currently owned by institutional investors.
Shares of Aptevo Therapeutics (APVO) traded down $0.03 during trading on Friday, reaching $3.37. The company’s stock had a trading volume of 92,440 shares, compared to its average volume of 276,107. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.67 and a current ratio of 7.76. Aptevo Therapeutics has a 52-week low of $1.15 and a 52-week high of $4.85.
Aptevo Therapeutics (NASDAQ:APVO) last announced its earnings results on Thursday, November 9th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $2.25 by ($2.11). Aptevo Therapeutics had a net margin of 5.40% and a negative return on equity of 28.03%. research analysts forecast that Aptevo Therapeutics will post 0.43 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Aptevo Therapeutics Inc (APVO) Receives Consensus Rating of “Strong Buy” from Analysts” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.com-unik.info/2018/01/31/aptevo-therapeutics-inc-apvo-receives-consensus-rating-of-strong-buy-from-analysts.html.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.